The alternative pyrogeneous test product (MylcMAT) using human immortalized monocyte cells (aMylc), begins shipping paid prototypes to Europe.

We are pleased to announce that we have started shipping paid prototypes to contract evaluation companies in Europe. We have received a lot of positive feedback from European companies after our presentation at the PharmaLab Congress, one of the largest safety testing conferences in Europe last year, and we have received inquiries about product trials. In January of this year, we established a European Development Office at Biolabs Heidelberg in Germany, and are ready to provide customer support. We will provide prototypes to European customers and conduct demonstrations at the European Development Office in Germany to improve product perfection based on feedback from European customers and prepare for the supply of MylcMAT products to the European market. We plan to make MylcMAT available to the European market as soon as possible.